CRVS
Price
$3.90
Change
+$0.15 (+4.00%)
Updated
Jun 5, 04:59 PM (EDT)
Capitalization
301.13M
68 days until earnings call
VKTX
Price
$27.04
Change
+$0.04 (+0.15%)
Updated
Jun 5, 04:59 PM (EDT)
Capitalization
3.04B
48 days until earnings call
Interact to see
Advertisement

CRVS vs VKTX

Header iconCRVS vs VKTX Comparison
Open Charts CRVS vs VKTXBanner chart's image
Corvus Pharmaceuticals
Price$3.90
Change+$0.15 (+4.00%)
Volume$7.95K
Capitalization301.13M
Viking Therapeutics
Price$27.04
Change+$0.04 (+0.15%)
Volume$188.25K
Capitalization3.04B
CRVS vs VKTX Comparison Chart
Loading...
CRVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VKTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRVS vs. VKTX commentary
Jun 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRVS is a Buy and VKTX is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 06, 2025
Stock price -- (CRVS: $3.90 vs. VKTX: $27.04)
Brand notoriety: CRVS and VKTX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRVS: 41% vs. VKTX: 72%
Market capitalization -- CRVS: $301.13M vs. VKTX: $3.04B
CRVS [@Biotechnology] is valued at $301.13M. VKTX’s [@Biotechnology] market capitalization is $3.04B. The market cap for tickers in the [@Biotechnology] industry ranges from $323.27B to $0. The average market capitalization across the [@Biotechnology] industry is $2.31B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRVS’s FA Score shows that 0 FA rating(s) are green whileVKTX’s FA Score has 0 green FA rating(s).

  • CRVS’s FA Score: 0 green, 5 red.
  • VKTX’s FA Score: 0 green, 5 red.
According to our system of comparison, VKTX is a better buy in the long-term than CRVS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRVS’s TA Score shows that 6 TA indicator(s) are bullish while VKTX’s TA Score has 5 bullish TA indicator(s).

  • CRVS’s TA Score: 6 bullish, 4 bearish.
  • VKTX’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, CRVS is a better buy in the short-term than VKTX.

Price Growth

CRVS (@Biotechnology) experienced а +2.76% price change this week, while VKTX (@Biotechnology) price change was -3.98% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.85%. For the same industry, the average monthly price growth was +10.46%, and the average quarterly price growth was -0.86%.

Reported Earning Dates

CRVS is expected to report earnings on Aug 12, 2025.

VKTX is expected to report earnings on Jul 23, 2025.

Industries' Descriptions

@Biotechnology (+7.85% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VKTX($3.04B) has a higher market cap than CRVS($301M). CRVS YTD gains are higher at: -29.907 vs. VKTX (-32.803). CRVS has higher annual earnings (EBITDA): -31.13M vs. VKTX (-171.93M). VKTX has more cash in the bank: 852M vs. CRVS (44.2M). VKTX has less debt than CRVS: VKTX (1M) vs CRVS (1.15M). CRVS (0) and VKTX (0) have equivalent revenues.
CRVSVKTXCRVS / VKTX
Capitalization301M3.04B10%
EBITDA-31.13M-171.93M18%
Gain YTD-29.907-32.80391%
P/E RatioN/AN/A-
Revenue00-
Total Cash44.2M852M5%
Total Debt1.15M1M115%
FUNDAMENTALS RATINGS
CRVS vs VKTX: Fundamental Ratings
CRVS
VKTX
OUTLOOK RATING
1..100
2274
VALUATION
overvalued / fair valued / undervalued
1..100
65
Fair valued
42
Fair valued
PROFIT vs RISK RATING
1..100
9174
SMR RATING
1..100
9534
PRICE GROWTH RATING
1..100
4787
P/E GROWTH RATING
1..100
98100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VKTX's Valuation (42) in the Biotechnology industry is in the same range as CRVS (65) in the Pharmaceuticals Major industry. This means that VKTX’s stock grew similarly to CRVS’s over the last 12 months.

VKTX's Profit vs Risk Rating (74) in the Biotechnology industry is in the same range as CRVS (91) in the Pharmaceuticals Major industry. This means that VKTX’s stock grew similarly to CRVS’s over the last 12 months.

VKTX's SMR Rating (34) in the Biotechnology industry is somewhat better than the same rating for CRVS (95) in the Pharmaceuticals Major industry. This means that VKTX’s stock grew somewhat faster than CRVS’s over the last 12 months.

CRVS's Price Growth Rating (47) in the Pharmaceuticals Major industry is somewhat better than the same rating for VKTX (87) in the Biotechnology industry. This means that CRVS’s stock grew somewhat faster than VKTX’s over the last 12 months.

CRVS's P/E Growth Rating (98) in the Pharmaceuticals Major industry is in the same range as VKTX (100) in the Biotechnology industry. This means that CRVS’s stock grew similarly to VKTX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRVSVKTX
RSI
ODDS (%)
Bearish Trend 2 days ago
71%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
77%
Momentum
ODDS (%)
Bullish Trend 2 days ago
87%
Bearish Trend 2 days ago
87%
MACD
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
78%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
86%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
87%
Advances
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 2 days ago
82%
Declines
ODDS (%)
Bearish Trend 15 days ago
90%
Bearish Trend 4 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 7 days ago
88%
Aroon
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
CRVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VKTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
WTRCX12.06N/A
N/A
Macquarie Core Equity Fund Class C
AMECX26.25N/A
N/A
American Funds Income Fund of Amer A
LICSX16.88N/A
N/A
Lord Abbett International Equity R4
NDGIX23.02N/A
N/A
Neuberger Berman Dividend Growth I
RINTX47.89-0.03
-0.06%
Russell Inv International Devd Mkts S

CRVS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRVS has been loosely correlated with SYRE. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if CRVS jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRVS
1D Price
Change %
CRVS100%
-8.98%
SYRE - CRVS
37%
Loosely correlated
-0.30%
VKTX - CRVS
35%
Loosely correlated
+1.47%
IPSC - CRVS
34%
Loosely correlated
-0.54%
FULC - CRVS
34%
Loosely correlated
-0.07%
VCYT - CRVS
33%
Poorly correlated
+2.98%
More